Real-World Experience with Anti-CGRP Migraine Antibodies in Large US Health Plan | Research

The takeaway

Large real-world study reports treatment persistence, patient satisfaction, and outcomes with anti-CGRP monoclonal antibodies for migraine prevention in a US healthcare network.

Real-world persistence data
Large US health plan tracking anti-CGRP antibody use patterns and patient satisfaction

What the researchers found

Real-world data from a large US healthcare plan demonstrates treatment persistence patterns and patient satisfaction with self-injectable anti-CGRP monoclonal antibodies for migraine prevention.

Why it matters

Clinical trial results don't always match real-world experience. This study provides the data patients and doctors need to make informed migraine treatment decisions.

How the study worked

Observational real-world study (Migraine Signature Study) of patients prescribed ≥1 self-injectable anti-CGRP mAb in a large US healthcare network, measuring persistence and patient-reported outcomes.

What this study cannot tell us

Observational design — no control group. Self-reported outcomes may have recall bias. Single healthcare plan may not represent all patient populations.

How to read the evidence

Large observational real-world study — provides valuable practical data but lacks the rigor of controlled trials.

When this study was published

Published in 2026; reflects mature anti-CGRP prescribing patterns.

The bigger picture

Real-world evidence is essential for understanding the true value of migraine preventive therapies as they mature beyond initial clinical trial enthusiasm.

Questions still open

What factors predict who will persist on anti-CGRP therapy long-term?
How do satisfaction levels compare across different anti-CGRP antibodies?

Common questions

Do anti-CGRP migraine drugs work in real life?

This large real-world study shows that anti-CGRP antibodies provide meaningful migraine prevention outside of clinical trials, though individual responses vary and some patients discontinue treatment.

How long should I try anti-CGRP therapy?

Guidelines typically recommend at least 3 months to assess response. This study provides real-world data on how long patients actually stay on these medications and their satisfaction levels.

Read the original research

Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study.

Neurology and therapy, 15(1), 401-420

View on PubMed ↗Publisher’s paper ↗

Citation

Buse, Dawn C; Lipton, Richard B; Urman, Robert; Vaidya, Shruti J; Robinson, Sarah C; Jacobson, Alice S; Scott, Alexandra B; Bensink, Mark E; Pressman, Alice R. (2026). Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study.. Neurology and therapy, 15(1), 401-420. https://doi.org/10.1007/s40120-025-00872-1